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Background: This study was aimed to investigate whether ATP-sensitive potassium channel (KATP) is involved in
curcumin’s anti-proliferative effects against gastric cancer.
Methods: In an in vitro study, gastric cancer cell line SGC-7901 was treated with curcumin at serial concentrations
and co-administrated with the KATP opener, diazoxide. The effect of curcumin and diazoxide on proliferation were
assessed by MTT assay. Mitochondrial membrane potential (MMP) was studied by flow cytometry detection of
rhodamine 123 staining. Apoptosis was evaluated by flow cytometry detection of Annexin V propidium iodide
double staining. In an in vivo study, SGC-7901 cells were planted into nude mice as xenografts. Animals were
treated with curcumin co-administered with diazoxide. Tumor volume and tumor weight were observed.
Results: Curcumin incubation significantly induced loss of MMP in SGC-7901 cells in a dose- dependent manner
(P < 0.05); the cell apoptotic rate also dramatically increased after curcumin incubation in a dose-dependent manner
(P < 0.05). After co-administration with diazoxide, however, we found that both the MMP-loss-inducing and the
apoptosis-inducing effects of curcumin in SGC-7901 cells were significantly impaired (all P < 0.05). As a result, the
proliferation of SGC-7901 cells was maintained by diazoxide treatment.
Conclusions: Impaired mitoKATP opening causes MMP loss, and is involved in curcumin-induced apoptosis in
gastric cancer.
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As the third leading cause of death in men and fourth in
women with malignant tumors, gastric cancer is now
threatening people’s lives worldwide [1]. Gastric cancer
is one of the highly malignant carcinomas arising from
epithelial cells, and is characterized by therapeutic ineffi-
ciency and poor prognosis [2]. Like most malignant tu-
mors, the malignancy of gastric cancer is caused by
uncontrolled cell proliferation, invasion, and metastasis.
The therapeutic options for gastric cancer are often lim-
ited because most patients with gastric cancer are* Correspondence: Zhangxu64@163.com; hxd@lzu.edu.cn
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unless otherwise stated.diagnosed at an advanced stage [3]. Currently, chemo-
therapy and radiotherapy are employed to treat gastric
cancer at an advanced stage. However, the side effects of
these therapies restrict their application and lower the
quality of life of patients [4]. Traditional Chinese medi-
cine has been effectively applied in treating malignant
diseases for a long time in Eastern Asia [5]. Several
monomers, including curcumin, discovered from trad-
itional Chinese medicine formulas have been shown to
have anti-cancer activities in previous studies [6]. How-
ever, the molecular mechanisms for these activities are
still unclear.
Natural extracts or products have attracted attention and
become the focus of anti-cancer drug research because
over two-thirds of novel anti-cancer drugs discovered in
recent decades are of natural original [7]. Curcumin, also
known as diferuloylmethane, is extracted from the rhizomes is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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curcumin is thought to be wide, including anti-angiogenic,
anti-oxidant, anti-inflammatory and anti-diabetic effects
[8]. Previous studies have shown that the expression of on-
cogenes [9], transcription factors [10], cytokines, and
growth factors [11] was modulated in the anti-cancer ef-
fects of curcumin. Although several mechanisms regulating
proliferation and apoptosis of curcumin have been investi-
gated, many more studies are still needed.
ATP-sensitive potassium channels, also referred to as
KATP, are distributed throughout the organs and tissues,
including skeletal muscle, cardiac muscle, brain, and kid-
ney [12]. KATP is characterized by a hetero-octameric
molecular structure; it is composed of four Kir6 and four
sulphonylurea receptor subunits [13]. It is now believed
that the fundamental function of KATP is to adjust mem-
brane excitability to cellular metabolic status [14]. KATP
located on the mitochondrial membrane is called mito-
KATP, the opening of which reduces the mitochondrial
transition opening permeability by increasing the activity
of inwardly rectifying potassium channels under stressful
conditions [15,16]. Thus, opening of the mitoKATP could
attenuate cell apoptosis by maintaining mitochondrial
membrane potential (MMP) [17].
A recent study preliminarily established the relation-
ship between mitoKATP and the proliferation of malig-
nant cancer cells, such as glioma cells [18]. This association
aroused our interests in exploring whether the possibility
that curcumin’s anti-cancer effect on gastric cancer is re-
lated to mitoKATP. In this study, we investigated the effect
of curcumin and the selective mitoKATP opener diazoxide
on proliferation, mitochondrial transition opening perme-
ability, and apoptosis in human gastric cancer cells SGC-
7901 in vitro. A corresponding in vivo study was also
implemented. Our results will contribute to a deepened un-
derstanding of the molecular mechanisms of curcumin’s
anti-cancer activity.Methods
Cell culture and treatment
Human gastric cancer cell line SGC-7901 was purchased
from the American Type Culture Collection and cul-
tured in DMEM (Gibco) supplemented with 10% FBS
(Gibco). The cells were maintained in a humidified cell
incubator (Thermo Scientific, Pittsburgh, PA, USA) con-
taining 5% CO2 at 37°C. Equal numbers of cells were di-
vided into seven independent groups: a control group
(C), a low-dose curcumin group (LCur), a medium-dose
curcumin group (MCur), a high-dose curcumin group
(HCur), a low-dose curcumin group treated with diazox-
ide (LCur + DZ), a medium-dose curcumin group treated
with diazoxide (MCur + DZ) and a high-dose curcumin
group treated with diazoxide (HCur + DZ).In the control group, cells were maintained in culture
medium, as described; in LCur, cells were treated with
curcumin (Sigma-Aldrich, St. Louis, MO, USA) solution
at concentration of 15 μmol/l; in MCur, cells were
treated with curcumin solution at a concentration of
30 μmol/l; in HCur, cells were treated with curcumin at
a concentration of 60 μmol/l; in LCur + DZ, cells were
treated with diazoxide (Sigma-Aldrich) at a concentra-
tion of 100 μmol/l together with curcumin at a concentra-
tion of 15 μmol/l; in MCur +DZ, cells were treated with
diazoxide at a concentration of 100 μmol/l together with
curcumin at a concentration of 30 μmol/l; in HCur + DZ,
cells were treated with diazoxide at concentration of




bromide (MTT) assay was employed to assess the prolif-
eration of SGC-7901 cells. Briefly, 1 × 104 cells per well
were planted in a 96-well culturing plate (Corning Co-
star, Corning, NY, USA) for 24 hours and then treated
with diazoxide and curcumin, as described. Then 20 μl
MTT (Sigma-Aldrich, 5 mg/ml, dissolved in PBS) was
added to each well and 150 μl dimethylsulfoxide (Sigma-
Aldrich) was added to replace medium from each well.
Absorbance at 450 nm (A450) was measured using a
plate reader (Bio-Rad, Hercules, CA, USA). The growth
inhibition rate was calculated using the formula:
Inhibition rate ¼ 1‐ A450treatment=A450controlð Þ½ 
100%
Cell apoptosis assay
The apoptosis assessment of SGC-7901 cells in each
group was carried out by flow cytometry using an
Annexin V-FITC Apoptosis Detection Kit (BD, San Jose,
CA, USA) as described previously [19]. Briefly, equal
numbers of cells from each group were washed by PBS
and titrated by binding buffer to concentrations of 1 ×
106 cell/ml. Then 100 μl of this cell suspension, 5 μl
Annexin V-FITC solution and 5 μl propidium iodide
were added to a culture tube for 15 min incubation in a
dark chamber. After 400 μl binding buffer was added to
each tube, apoptosis was then analyzed by a fluorescence-
activated cell sorting flow cytometer (BD, San Jose, CA,
USA).
Mitochondrial membrane potential (MMP) detection
The MMP in SGC-7901 cells was determined by detec-
tion of rhodamine 123 staining by flow cytometry fol-
lowing the protocols described in a previous study [19].
Cells from each group were washed by PBS twice then
Figure 1 Effects of curcumin and its co-administration with
diazoxide on proliferation of SGC-7901 cells. Cell proliferation was
assessed by MTT assay. Graphs shows inhibition rate of SGC-7901 cells
treated by curcumin (red) and co-administration of curcumin and
diazoxide (green). Values are represented as mean ± standard
deviation. *, values are significantly different when compared with
control; #, values are significantly different when compared with
curcumin treatment.
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(Beyotime, Shanghai, China) was then added to the cell
suspension at a final concentration of 1 μmol/l. After in-
cubation at 37°C in a dark chamber for 30 min, the
fluorescent signal of rhodamine 123 released from cells
was analyzed by a fluorescence-activated cell sorting
flow cytometer (BD, San Jose, CA, USA) at 529 nm.
In vivo xenograft tumor study
Cultured SGC-7901 cells were suspended and titrated in
PBS at a concentration of 1 × 107/ml. 100 μl of the cell
suspension was subcutaneously injected into the right
armpits of male BALB/C nude mice (Animal Experimen-
tal Center of the Fourth Military Medical University)
with a mean body weight of (17.64 ± 5.19) g. After the
volumes of the xenograft tumors exceeded 100 mm3, 18
mice were divided into three independent groups ran-
domly and evenly (six mice per group); namely, a control
group (C), a curcumin treatment group (Cur) and curcu-
min and diazoxide co-treatment group (Cur + DZ). In
Cur + DZ, mice received peritumoral injections of curcu-
min (50 mg/kg) applied together with peritumoral injec-
tions of diazoxide (10 mg/kg) twice per day for 2 weeks.
In Cur, mice received peritumoral injections of curcumin
(50 mg/kg) twice per day for 2 weeks. In C, mice re-
ceived peritumoral injections of physiological saline
twice per day for 2 weeks. The animal treatment proto-
cols were in accordance with our pre-experimental re-
sults (not shown) and several previous studies [20,21].
The volume of tumor was measured twice per week and
calculated by the formula:
Volume ¼ Length Width2  1=2
The tumor was also weighted after the mice were sacri-
ficed. All animal experimental procedures were performed
in accordance with the National Institutes of Health Guide
for the Care and Use of Laboratory Animals.
Statistical considerations
All data collected in this study are expressed as mean ±
standard deviation. The statistical analysis was processed
by software SPSS (version 16.0) by analysis of variance
(ANOVA), least-significant difference and Fisher exact
tests. P < 0.05 was considered statistically significant
when comparing differences.
Results
Curcumin inhibited proliferation of SGC-7901 cells but
this was alleviated by diazoxide co-administration
As shown in Figure 1, according to the results of the
MTT assay, curcumin elevated inhibition rate in a
concentration-dependent manner in LCur (9.5% ±
2.10%), MCur (23.2% ± 7.21%), and HCur (39.4% ±9.43%) compared with C (1.20% ± 0.25) (all P < 0.05).
However, after co-administration of diazoxide, the inhib-
ition rate was decreased in LCur + DZ (6.72% ± 1.80%),
MCur + DZ (16.55% ± 6.11%), and HCur + DZ (31.43 ±
8.15%) compared with corresponding LCur, MCur, and
HCur (all P < 0.05).
Co-administration of diazoxide impaired curcumin’s
effects of decreasing mitochondrial membrane potential
(MMP) in SGC-7901 cells
In a concentration-dependent manner (Figure 2), curcu-
min lowered MMP in SGC-7901 cells in LCur (77.51% ±
8.13%), MCur (62.07% ± 4.52%), and HCur (59.18% ±
9.30%) compared with C (95.40% ± 7.62%) (all P < 0.05).
However, MMP was significantly higher with the co-
administration of diazoxide; LCur + DZ (87.33% ± 4.68%),
MCur + DZ (59.18% ± 5.92%), and HCur + DZ (65.29% ±
6.10%) (all P < 0.05).
Co-administration of diazoxide mitigated apoptosis in
curcumin-incubated SGC-7901 cells
Detected by flow cytometry, compared with C (2.44% ±
0.79%) the apoptosis rate of SGC-7901 cells was in-
creased by curcumin incubation in a concentration-
dependent manner in LCur (18.94% ± 2.32%), MCur
(35.21% ± 2.77%), and HCur (63.09% ± 3.05%) (all P <
0.05). When applied together, diazoxide alleviated the
curcumin-induced apoptosis in LCur + DZ (13.51% ±
1.85%), MCur + DZ (27.81% ± 2.24%), and HCur + DZ
(54.22% ± 2.72%). The results are shown in Figure 3.
Figure 2 Effects of curcumin and its co-administration with diazoxide on mitochondrial membrane potential in cultured SGC-7901
cells. Cells were stained with rhodamine 123 and then detected by a flow cytometer. Cells with decreased MMP show less detected fluorescence
from rhodamine 123. Charts of flow cytometry from top to bottom and from left to right show the detected rhodamine 123 fluorescence of C,
LCur, LCur + DZ, MCur, MCur + DZ, HCur, and HCur + DZ. C, control; DZ, diazoxide; FITC, fluorescein isothiocyanate; HCur, high-dose curcumin;
LCur, low-dose curcumin; MCur, medium-does curcumin; MMP, mitochondrial membrane potential.
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reversed by co-administration of diazoxide in vivo
At the end of 3 weeks after initiation of curcumin and
diazoxide treatment, all mice were alive. After sacrifice, tu-
mors were isolated. Compared with C, tumor volume was
significantly reduced in Cur starting from day 7 (P < 0.05).
However, tumor volume in Cur +DZ was significantly
higher than that in Cur (P < 0.05). In Cur, curcumin ad-
ministration showed a significant inhibitory effect on the
weight of xenografts compared with C (P < 0.05). How-
ever, this effect was mitigated by co-administration of
diazoxide (P < 0.05). The results are shown in Figure 4.
Discussion
We explored the involvement of KATP in the anti-
proliferation effects of curcumin in gastric cancer. It wasfound that curcumin could inhibit the proliferation of
gastric cancer cells by inducing apoptosis. Our in vitro
results showed that curcumin-induced apoptosis of
SGC-7901 cells by facilitating the collapse of MMP,
which was believed to initiate the mitochondria-dependent
apoptotic pathway. However, the co-administration of diaz-
oxide, which is a mitoKATP selective opener, alleviated the
collapse of MMP in curcumin-incubated SGC-7901 cells.
In our in vivo study, the reduction in both volume and
weight of xenograft tumor by curcumin was also reversed
by co-administration of diazoxide. These results indicated
that curcumin could induce apoptosis of gastric cancer
cells via deactivating mitoKATP, which would expedite the
collapse of MMP.
With the improvement of modern medical technology
and cancer prevention, the incidence of gastric cancer
Figure 3 Effects of curcumin and its co-administration with diazoxide on apoptosis of SGC-7901 cells. Cells were double-stained with
Annexin V and propidium iodide, and apoptosis rates were analyzed by flow cytometry. Percentage on the right top corner of each chart stands
for apoptosis rate. Charts of flow cytometry from top to bottom, from left to right show the detected rhodamine 123 fluorescence of C, LCur,
LCur + DZ, MCur, MCur + DZ, HCur and HCur + DZ, respectively. C, control; DZ, diazoxide; HCur, high-dose curcumin; LCur, low-dose curcumin;
MCur, medium-does curcumin, PI; propidium iodide.
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However, globally, gastric cancer is now the second lead-
ing cause of mortality in malignant diseases [1]. The
prognosis of patients with gastric cancer is poor, espe-
cially in patients with metastatic lymph nodes and low
serum albumin levels, who are considered not suitable
for surgical treatment [23]. Owing to the unapparent
and sneaky clinical manifestations of early stage gastric
cancer, patients are often only diagnosed when the can-
cer is at an advanced stage [24]. Thus, the current most
curative therapy, surgery [25], is excluded from treat-
ment strategies. Alternative therapies, including chemo-
therapy, radiotherapy, and radiochemotherapy, thougheffective, are none of them curative. In recent decades,
several natural products originating from medicinal
herbs have broadened our understanding because of
their extensive biological activities [26]. Such drugs as
emodin [27], curcumin [28], and matrine [29] have been
demonstrated to have anti-cancer effects by inhibiting
proliferation, invasion, and metastasis of multiple malignant
cancers. Although many studies revealed their pharmaco-
logical mechanisms, much research is still needed.
Used as a coloring agent, spice, and flavoring, curcu-
min has also been widely applied since ancient times in
medical systems in Eastern and Southeastern Asia as
an important ingredient of medicinal formulas [30].
Figure 4 Effects of curcumin and its co-administration with diazoxide on growth of SGC-7901 tumor xenografts. (A) Isolated tumor
xenografts from nude mice of Cur, Cur + DZ, and C at day 21. (B) Weight of isolated xenografts from nude mice of Cur, Cur + DZ, and C at day
21. (C) Tumor volume of SGC-7901 tumor xenografts in Cur (blue), Cur + DZ (green) and C (red) from day 1 to day 21. Values are represented as
mean ± standard deviation. *, values are significantly different compared with C; #, values are significantly different compared with Cur. C, control;
Cur, curcumin; DZ, diazoxide.
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extracted from the rhizome of a herb named Curcuma
Longa Linn, exerted potent anti-cancer activity by inhi-
biting cell proliferation in vitro and in vivo [31]. The
mechanisms involved in curcumin’s proliferation inhib-
ition were thought to be complicated: multiple pathways
and molecular mediators were proved relevant. It was
believed that three canonical apoptotic pathways, namely
the death receptor [32], mitochondrial [33], and endo-
plasmic reticulum stress [34] pathways, were activated to
induce apoptosis of cancer cells. Some transcriptional
factor-related mechanisms, such as downregulation of
TNF-induced nuclear factor κB mediated gene expres-
sions [35] by curcumin were also indicated [36]. A re-
cent report of the involvement of mitoKATP in regulating
proliferation, invasion, and metastasis in glioma cells
[37] provided new clues to the mechanisms of curcu-
min’s anti-proliferation effects.
It was suggested that KATP channels were distributed
throughout the body, located on cell membranes and
mitochondrial membranes, including malignant cells
[38]. The major function of mitoKATP was supposed to
be to adjust mitochondrial membrane functions toexternal stressors by opening the ion channel. Most
studies concerning mitoKATP have been on cardiac
ischemia-reperfusion injuries [39]. Results from these
studies suggest that opening of mitoKATP channels could
protect against apoptosis [40]. At the early stage of
apoptosis, the opening of mitoKATP could inhibit
depolarization of mitochondrial membrane to maintain
MMP [41]. Thus, the mitochondrial membrane was sta-
bilized to prevent further apoptotic chain reaction, such
as transition pore formation, cytochrome c release or
caspase cascade activation. Diazoxide is a widely used
antihypertensive agent that acts as a selective opener of
mitoKATP to modulate the loss of MMP [42,43]. As a
result, diazoxide could further protect cells from
apoptosis.
In this study, to test the participation of mitoKATP in
curcumin-induced apoptosis of SGC-7901 cells, diazox-
ide was co-administrated with curcumin to incubate
SGC-7901 cells. The results of an in vitro study indi-
cated that diazoxide co-administration alleviated the
apoptosis of SGC-7901 by stabilizing MMP. The co-
administration of diazoxide impaired curcumin’s inhibi-
tory effects against xenograft tumor growth. The results
Liu et al. World Journal of Surgical Oncology 2014, 12:389 Page 7 of 8
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in vitro study that impaired mitoKATP is one of the pos-
sible mechanisms of curcumin’s anti-proliferative effects
against gastric cancer.
Conclusions
We can conclude that:
1. Curcumin inhibits proliferation of gastric cancer by
inducing apoptosis.
2. Impaired mitoKATP opening causes MMP loss, and
is involved in curcumin-induced apoptosis in gastric
cancer.
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